期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 55, 期 22, 页码 9393-9413出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm300915b
关键词
-
资金
- Cancer Research UK
- GlaxoSmithKline
- Pfizer Neusentis
- UCB
- Structural Genomics Consortium [1097737]
- Canadian Institutes for Health Research
- Canada Foundation for Innovation
- Genome Canada
- Pfizer
- Eli Lilly
- Novartis Research Foundation
- Ontario Ministry of Research and Innovation
- Wellcome Trust
- Cancer Research UK [6947] Funding Source: researchfish
Bromodomains, protein modules that recognize and bind to acetylated lysine, are emerging as important components of cellular machinery. These acetyl-lysine (KAc) reader domains are part of the write-read-erase concept that has been linked with the transfer of epigenetic information. By reading KAc marks on histones, bromodomains mediate protein-protein interactions between a diverse array of partners. There has been intense activity in developing potent and selective small molecule probes that disrupt the interaction between a given bromodomain and KAc. Rapid success has been achieved with the BET family of bromodomains, and a number of potent and selective probes have been reported. These compounds have enabled linking of the BET bromodomains with diseases, including cancer and inflammation, suggesting that bromodomains are druggable targets. Herein, we review the biology of the bromodomains and discuss the SAR for the existing small molecule probes. The biology that has been enabled by these compounds is summarized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据